Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020.
Mollie S H FriedlanderNicolas J BetancourtAlain PinedaNolan J MaloneyKevin A NguyenSunil A ReddyEvan T HallSusan M SwetterLisa C ZabaPublished in: The oncologist (2022)
Amid the evolving landscape of systemic therapy for advanced melanoma, nivolumab monotherapy emerged as the most used and least costly systemic treatment from 2016 to 2020. Its sharp increase in use in 2018 and lower costs relative to pembrolizumab may in part be due to earlier adoption of less frequent dosing intervals.